Gibadullin Ruslan, Farnsworth David Wayne, Barchi Joseph J, Gildersleeve Jeffrey C
Chemical Biology Laboratory, National Cancer Institute, National Institutes of Health , 376 Boyles St., Frederick, Maryland 21702, United States.
ACS Chem Biol. 2017 Aug 18;12(8):2172-2182. doi: 10.1021/acschembio.7b00471. Epub 2017 Jul 14.
In 2011, a new type of protein O-glycosylation was discovered in which N-acetylgalactosamine is attached to the side chain of tyrosine (GalNAc-Tyr). While present on dozens of proteins, the biological roles of GalNAc-Tyr are unknown. To gain insight into this new type of modification, we synthesized a group of GalNAc-Tyr glycopeptides, constructed microarrays, and evaluated potential recognition of GalNAc-Tyr by a series of glycan-binding proteins. Through a series of >150 microarray experiments, we assessed binding properties of a variety of plant lectins, monoclonal antibodies, and endogenous lectins. VVL, HPA, and SBA were all found to bind tightly to GalNAc-Tyr, and several Tn binding antibodies and blood group A antibodies were found to cross-react with GalNAc-Tyr. Thus, detection of GalNAc-Tyr modified proteins is an important consideration when analyzing results from these reagents. Additionally, we evaluated potential recognition by two mammalian lectins, human (hMGL) and murine (mMGL-2) macrophage galactose type C-type lectins. Both hMGL and mMGL-2 bound tightly to GalNAc-Tyr determinants. The apparent K values (∼1-40 nM) were on par with some of the best known ligands for MGL, such as the Tn antigen. hMGL also bound the natural beta-amyloid peptide containing a GalNAc-Tyr epitope. STD NMR experiments provided structural insights into the molecular basis of recognition. Finally, GalNAc-Tyr was selectively captured by mMGL-2 positive dendritic cells. These results provide the first evidence that GalNAc-Tyr modified proteins and/or peptides may be ligands for hMGL and mMGL-2 and offer unique structures for the design of MGL targeting agents.
2011年,人们发现了一种新型蛋白质O-糖基化,其中N-乙酰半乳糖胺连接到酪氨酸的侧链上(GalNAc-Tyr)。虽然在几十种蛋白质上都有发现,但GalNAc-Tyr的生物学作用尚不清楚。为了深入了解这种新型修饰,我们合成了一组GalNAc-Tyr糖肽,构建了微阵列,并评估了一系列聚糖结合蛋白对GalNAc-Tyr的潜在识别能力。通过一系列超过150次的微阵列实验,我们评估了多种植物凝集素、单克隆抗体和内源性凝集素的结合特性。发现VVL、HPA和SBA都能紧密结合GalNAc-Tyr,并且发现几种Tn结合抗体和血型A抗体与GalNAc-Tyr发生交叉反应。因此,在分析这些试剂的结果时,检测GalNAc-Tyr修饰的蛋白质是一个重要的考虑因素。此外,我们评估了两种哺乳动物凝集素,即人(hMGL)和小鼠(mMGL-2)巨噬细胞半乳糖型C型凝集素的潜在识别能力。hMGL和mMGL-2都能紧密结合GalNAc-Tyr决定簇。表观K值(约1-40 nM)与MGL一些最知名的配体相当,如Tn抗原。hMGL还结合了含有GalNAc-Tyr表位的天然β-淀粉样肽。STD NMR实验提供了对识别分子基础的结构见解。最后,GalNAc-Tyr被mMGL-2阳性树突状细胞选择性捕获。这些结果提供了首个证据,表明GalNAc-Tyr修饰的蛋白质和/或肽可能是hMGL和mMGL-2的配体,并为设计MGL靶向剂提供了独特的结构。